Abstract:BackgroundGPRC6A is implicated in the pathogenesis of prostate cancer, but its role remains uncertain because of a purported tolerant gene variant created by substitution of a K..Y polymorphism in the 3rd intracellular loop (IL) that evolved in the majority of humans and replaces the ancestral RKLP present in 40% of humans of African descent and all other species.MethodsWe determined whether the K..Y polymorphism is present in human-derived prostate cancer cell lines by sequencing the region of the 3rd IL and assessed the cellular localization of a “humanized” mouse GPRC6A containing the K..Y sequence by immunofluorescence. We assessed functions of GPRC6A in PC-3 cells expressing endogenous GPRC6A and in GPRC6A-deficient PC-3 cells created using CRISPR/Cas9 technology. The effect of GPRC6A on basal and ligand stimulated cell proliferation and migration was evaluated in vitro in wild-type and PC-3-deficient cell lines. The effect of editing GPRC6A on prostate cancer growth and progression in vivo was assessed in a Xenograft mouse model implanted with wild-type and PC-3 deficient cells and treated with the GPRC6A ligand osteocalcin.ResultsWe found that all of the human prostate cancer cell lines tested endogenously express the “K..Y” polymorphism in the 3rd IL. Comparison of mouse wild-type GPRC6A with a “humanized” mouse GPRC6A construct created by replacing the “RKLP” with the “K..Y” sequence, found that both receptors were predominantly expressed on the cell surface. The transfected “humanized” GPRC6A receptor, however, preferentially activated mTOR compared to ERK signaling in HEK-293 cells. In contrast, in PC-3 cells expressing the endogenous GPRC6A with the “K..Y” polymorphism, the ligand osteocalcin stimulated ERK, AKT and mTOR phosphorylation, promoted cell proliferation and migration, and upregulated genes regulating testosterone biosynthesis. Targeting GPRC6A in PC-3 cells by CRISPR/Cas9 significantly blocked these responses in vitro. In addition, GPRC6A deficient PC-3 xenografts exhibited significantly less growth and were resistant to osteocalcin-induced prostate cancer progression compared to control PC-3 cells expressing GPRC6A.ConclusionsHuman GPRC6A is a functional osteocalcin and testosterone sensing receptor that promotes prostate cancer progression. GPRC6A may contribute to racial disparities in prostate cancer, and is a potential therapeutic target to develop antagonists to treat prostate cancer.

Gprc5a is a novel parathyroid hormone‐inducible gene and negatively regulates osteoblast proliferation and differentiation

G Protein and its signaling pathway in bone development and disease.

GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer

PTH-Induced Osteoblast Proliferation Requires Upregulation of the Ubiquitin-Specific Peptidase 2 (Usp2) Expression

Structural Basis of Activation and Sustained Signaling by the PTH Receptor

Inhibition of Phosphodiesterase 5 Reduces Bone Mass by Suppression of Canonical Wnt Signaling

PTHrP expression in human MDA-MB-231 breast cancer cells is critical for tumor growth and survival and osteoblast inhibition

GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice

Targeting RACGAP1 Suppresses Growth Hormone Pituitary Adenoma Growth

Regulation of Bone Formation and Remodeling by G-Protein-Coupled Receptor 48

PTHG2 Reduces Bone Loss in Ovariectomized Mice by Directing Bone Marrow Mesenchymal Stem Cell Fate

GPRC5A: an Emerging Biomarker in Human Cancer

Calcitonin Gene-Related Peptide Induces Proliferation and Monocyte Chemoattractant Protein-1 Expression Via Extracellular Signal-Regulated Kinase Activation in Rat Osteoblasts

CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model

Method of Parathyroid Hormone Acting on Bone Metabolism--related Genes Expression of Old Rats' Bone Marrow Cells

Receptor activity-modifying protein modulation of parathyroid hormone-1 receptor function and signaling

Differential Effects of PTH (1-34), PTHrP (1-36), and Abaloparatide on the Murine Osteoblast Transcriptome

Receptor activity modifying protein modulation of parathyroid hormone-1 receptor function and signalling.

Mutual Up-Regulation of Thyroid Hormone and Parathyroid Hormone Receptors in Rat Osteoblastic Osteosarcoma 17/2.8 Cells1

[Effect of signal-selective parathyroid hormone analogue peptide on expressions of Wnt signaling factors]

TGF-β Induced PAR-1 Expression Promotes Tumor Progression and Osteoclast Differentiation in Giant Cell Tumor of Bone.